According to current guidelines, breast cancer risk assessment should be based primarily on the analysis of 14 genes: ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53. This evidence concerns the gene TP53 and breast carcinoma.